Digital Diabetes Still Alive

While shares of Livongo continue to struggle as we predicted deals in the digital diabetes space would go on. Just this morning we learned that Bayer is investing in … wait for it … OneDrop. Per the press release;

“One Drop, a leader in the development of digital therapeutic solutions for diabetes and other chronic conditions, today announced $40 million in Series B financing, led by Bayer, one of the largest pharmaceutical companies in the world. Bayer has also entered a commercial licensing agreement to use One Drop’s platform in Bayer’s global bio-digital efforts in therapeutic areas such as . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.